- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT03398122
Study of Apatinib Combined With TACE in Advance Hepatocellular Carcinoma (HCC)
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
HCC The is a common malignancy in the world, especially in China. Advanced HCC treatment is difficult and the prognosis is poor, which is still a great challenge and threat to the medical profession. The advent of the molecular targeted drug, Sola, has made the treatment dilemma of advanced HCC a breakthrough, but the efficacy and economic health ratio is far from satisfactory. After Sola, many new molecular targeted drugs were studied, but failed.
Although multiple treatment options, but for HCC Patient-recommended treatment programs require systematic treatment and surgery, TACE , local ablation and radiotherapy and other multidisciplinary means of combination, the selection of appropriate patients, appropriate means and timing to achieve individualized treatment.
1. Aptinib Union TACE can be generated through embolization and angiogenesis by the dual target of vascular suppression;2. TACE induces hypoxia, leading to an increase in the number of hypoxia-inducing factors that increases VEGF and PDGFR , while VEGF the and PDGFR may be important factors that induce tumor recurrence by stimulating tumor angiogenesis.
Studietype
Inschrijving (Verwacht)
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
- Naam: Haipeng Yu, MD
- Telefoonnummer: 13352070835
- E-mail: jieruke@yahoo.com.cn
Studie Contact Back-up
- Naam: Zhi Guo, MD
- Telefoonnummer: 18622221211
- E-mail: cjr.guozhi@vip.163.com
Studie Locaties
-
-
Tianjin
-
Tianjin, Tianjin, China, 300060
- Werving
- Tianjin Medical University Cancer Hospital
-
Contact:
- Haipeng Yu, MD
- Telefoonnummer: 13352070835
- E-mail: jieruke@yahoo.com.cn
-
Onderonderzoeker:
- Wenge Xing, MD
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Age: 18-70 years old;
- initial treatment diagnosed by histopathological or cytological examination BCLC Staging B/C Hepatocellular carcinoma of the liver ( HCC ) and at least one of the largest tumors in measurable lesions ≤15cm ;
- Child-pugh liver function Rating: A level, B level;
- BCLC Staging as B / C period;
before join in the group 1 weeks ECOG PS Rating: 0-1 score; estimated Lifetime ≥12 Week; Lab metrics meet the following criteria: ( 1 ) Blood routine check:
- HB≥90 g/L;
- ANC≥1.5x109/L;
- PLT≥60x109/L; ( 2 ) Biochemical Examination:
- ALB≥29 g/L;
- ALT and AST<2.5*ULN;
- TBIL ≤ 2*ULN;
- Cr ≤ 1.5*ULN;
- women of childbearing age must be pregnancy tests before join in the group in 7 days;
- Participants volunteered to join this study should sign informed consent, with good compliance and follow-up.
Exclusion Criteria:
- Central hepatic artery / hepatic venous fistula in patients with hepatocellular carcinoma, diffuse liver cancer patients, with large vascular invasion of liver cancer patients (including portal vein tumor thrombus);
- hepatobiliary cell carcinoma and mixed cell carcinoma are known; previous ( 5 year) or at the same time suffering from other incurable malignancies, except for the cured basal cell carcinoma of the skin and cervical carcinoma in situ;
- clinically symptomatic ascites that requires therapeutic celiac puncture or drainage with high blood pressure and cannot be reduced to normal range by anti hypertensive medications (systolic pressure > 140 mmHg , diastolic pressure >90 mmHg );
- Suffering Ⅱ above-level myocardial ischemia or myocardial infarction, control of poor arrhythmia (including QTC inter-phase male ≥450 ms , female ≥470 ms );
- Follow NYHA Standard Ⅲ ~ Ⅳ grade heart insufficiency or heart color Doppler ultrasonography: LVEF (left ventricular ejection fraction) < 50% ;
- There are various factors affecting oral medication (e.g.inability to swallow, chronic diarrhea and intestinal obstruction, which significantly affect drug use and absorption);
- previous within 6 months there is a history of gastrointestinal bleeding or a clear tendency to gastrointestinal bleeding, such as: bleeding risk of esophageal varices, local active ulcer lesions, fecal occult blood ≥ ( ++ ) not in group; fecal occult blood (+ ), requiring gastroscopy;
- before participating in this study There were abdominal fistula, gastrointestinal perforation or celiac abscess in the day;
- Coagulation dysfunction ( INR > 1.5 or prothrombin time ( PT ) > ULN+4 seconds), with bleeding tendencies or undergoing thrombolysis or anticoagulant therapy;
- patients who have undergone central nervous system metastasis or known brain metastases;
- patients with objective evidence of the history of pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonia, drug-related pneumonia, and severe lung impairment;
- urine proteins are routinely shown ≥++ or confirmed 24 hour urine protein ration > 1.0 g ;
- before participating in the study 7 days use strong-effect in CYP3A4 inhibitor therapy, or prior to participating in the study 12 days use the strong-effect in CYP3A4 inducer Therapy;
- pregnant or lactating women who are not willing or unable to take effective contraceptive measures;
- A history of mental illness, or psychotropic substance abuse;
- Union HIV infected patients;
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Niet-gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Experimenteel: Apatinib combined with TACE
patients received Aptinib, 250 mg daily after TACE treatment, for 4-6 weeks
|
epirubicin 30-60mg was injected into the blood supply artery of the tumor ,Embolization was subsequently performed with granules of gelatin sponge particles.
Andere namen:
a molecular targeted anti-tumor drugs,small molecule vascular endothelial growth factor receptor 2 inhibitor
Andere namen:
|
Placebo-vergelijker: chemoemtranscatherer arterial bolization
epirubicin 30-60mg was injected into the blood supply artery of the tumor ,Embolization was subsequently performed with granules of gelatin sponge particles.
|
a molecular targeted anti-tumor drugs,small molecule vascular endothelial growth factor receptor 2 inhibitor
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
PFS
Tijdsspanne: one and a half year
|
progression free survival
|
one and a half year
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
OS
Tijdsspanne: one and a half year
|
overall survival
|
one and a half year
|
TTP
Tijdsspanne: one and a half year
|
time to progression
|
one and a half year
|
DCR
Tijdsspanne: one and a half year
|
disease control rate
|
one and a half year
|
ORR
Tijdsspanne: one and a half year
|
objective response rate
|
one and a half year
|
QOL
Tijdsspanne: one and a half year
|
number of participants with treatment-related adverse events as assessed by EORTC QLQ-C30
|
one and a half year
|
Medewerkers en onderzoekers
Onderzoekers
- Studie stoel: Zhi Guo, MD, Tianjin Medical University Cancer Institute & Hospital
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Verwacht)
Studie voltooiing (Verwacht)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Ziekten van het spijsverteringsstelsel
- Neoplasmata per histologisch type
- Neoplasmata
- Neoplasmata per site
- Adenocarcinoom
- Neoplasmata, glandulair en epitheel
- Neoplasmata van het spijsverteringsstelsel
- Lever Ziekten
- Lever neoplasmata
- Carcinoom
- Carcinoom, hepatocellulair
- Moleculaire mechanismen van farmacologische werking
- Enzymremmers
- Antineoplastische middelen
- Proteïnekinaseremmers
- Apatinib
Andere studie-ID-nummers
- Ahead-HBH001
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Hepatocellulair carcinoom
-
Hospices Civils de LyonWervingKwaadaardige tumoren als Chordoma, Adenoid Cystic Carcinoma en SarcoomFrankrijk
-
CG Oncology, Inc.BeëindigdCarcinoom in Situ | Overgangscelcarcinoom | Blaaskanker | Carcinoma in situ gelijktijdig met papillaire tumorenVerenigde Staten
Klinische onderzoeken op TACE
-
AZ-VUBOnbekendDiabetes mellitus, type 1België
-
Tallac TherapeuticsWervingGevorderde of gemetastaseerde solide tumorenVerenigde Staten, Australië
-
Novartis PharmaceuticalsVoltooid
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); Taiho Pharmaceutical Co., Ltd.VoltooidLeverkankerVerenigde Staten
-
Taiho Pharmaceutical Co., Ltd.VoltooidVerkennende studie van TAC-302 bij patiënten met detrusor-onderactiviteit met een overactieve blaas.Overactieve blaas | Detrusor onderactiviteitJapan
-
Weill Medical College of Cornell UniversityNational Cancer Institute (NCI)VoltooidGeavanceerde kankerVerenigde Staten
-
Taiho Oncology, Inc.Quintiles, Inc.BeëindigdGeavanceerd hepatocellulair carcinoomJapan
-
Chia Nan University of Pharmacy & ScienceGlac Biotech Co., LtdVoltooid
-
Taiho Oncology, Inc.IngetrokkenGeavanceerd hepatocellulair carcinoom
-
Novartis PharmaceuticalsIngetrokken